[Experience of the Valdivia Hospital in renal transplant: an analysis of our first 100 cases]. / Experiencia del Hospital de Valdivia en trasplante renal: análisis de nuestros primeros 100 casos.

From September 1980 until October 1995 we have performed 100 renal transplant on 95 patients. Up to May of 1996 the medium follow-up was of 69.7 months (in a range of: 15 to 196 months). Seventy-nine kidney implants were performed from related living donors and 21 from dead donors. The average age of recipients was 35.8 years (SD: +/- 12.5 years). Chronic renal insufficiency of recipients is reviewed as well as their accompanying pathology. We found that in a 20% of the cases the donor's kidney had multiple renal arteries. In most of the ureteral vesical implantations were performed with Salvatierra's technique. Preservation cold time for the cadaveric donor kidneys was over 24 hours. In only a 33% of the cases Cyclosporine was used as the immunosuppression therapy. The 9% of ureteral complications are outlined. TBC is an important cause of complications and death of patients. To date there are 76 functioning kidney allografts and 14 lost graft kidneys. Ten patients have died, 3 of them with functional graft kidney. Actuarial graft survival rate for 1, 5 and 10 years are 92.7%, 78.7% and 59.3% respectively.

[Treatment of stage I nonseminomatous testicular cancer with one cycle of adjuvant chemotherapy]. / Tratamiento del cáncer testicular no seminoma etapa I con un ciclo de quimioterapia adyuvante.

On May 1990, we began a treatment protocol for testicular stage I nonseminomatous cancer, with one chemotherapy cycle consisting of a cisplatin based combination of drugs. Until July 1996 we had admitted 18 patients, presenting five of them embryonal carcinoma and three yolk sac tumors. So far, with a median follow-up of 46.9 months, we had not relapses. 11 patients have normal long term semen analysis, with two achieving pregnancy. We believe this is acceptable alternative for treating stage I nonseminomatous cancer with scarce drugs adverse reactions. The convenience of selecting patients previous admittance, is discussed.

[Prophylaxis of superficial bladder cancer with 1 mg of intravesical BCG: comparison with other doses]. / Profilaxis del cáncer vesical superficial con 1 mg de BCG endovesical: comparacion con otras dosis.

Presentation of results obtained in 171 evaluable patients from a series of 181, presenting surface vesical cancer in Tis, Ta and T1 stages, treated with 3 different dosages of endovesical BCG as prophylaxis for tumour relapse: a) high dose, 100 to 120 mg, 72 patients; b) intermediate dose, 20 to 50 mg, 39 patients; and, c) minidose of 1 mg, 60 patients. Complications and adverse reactions were seen to be dose-dependent, also percentage of patients free of disease both after treatment and following addition of retreatment in several patients was similar in all the dosages used. It is thus concluded that endovesical BCG 1 mg, would be an optimal dosage for the prophylaxis of surface vesical cancer relapse.

Adenocarcinoma renal: experiencia clínica y tratamiento / Renal adenocarcinoma: clinical experience and treatment

Revisamos 118 adenocarcinomas renales operados en un período de 20 años, con un seguimiento entre 1 y 20 años. La edad, sexo, sitio anatómico, diámetro tumoral y tiempo sintomático no influyeron en la sobrevida. Esta fue mejor a menor estadio tumoral, existiendo dfiferencias significativas en la sobrevida a 10 años, entre el estadio IIIa (58 por ciento) y IIIb (0 por ciento). Similares diferencias mostró el grado de Skinner (56,3 por ciento el grado bajo y 24,5 por ciento el grado alto) y el grado de Broders (54,5 por ciento el grado bajo y 13,7 por ciento el grado alto), corvirtiéndose ambos en exelentes factores pronósticos. No hubo diferencias estadísticas en la sobrevida según tipo histológico y arquitectura tumoral. El principal tratamiento fue la nefrectomía radical (70 por ciento), no encontándose diferencias según vía de abordaje